Project Grant 2605121
- Federal Grant Award Summary Award Details: Deleon Technologies, Inc. received a $305,000 Small Business Innovation Research (SBIR) Phase I project grant from the National Science Foundation's Directorate for Technology, Innovation, and Partnerships (TIP) under CFDA 47.084, awarded July 1, 2026, with completion targeted for June 30, 2027. Products and Services: The company will develop a low-cost, single-use microfluidic chip that performs capillary electrophoresis with laser-induced fluorescence...
- Federal Grant Award Summary Amygo Solutions LLC received a $304,643 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation's Directorate for Technology, Innovation, and Partnerships (CFDA 47.084) effective July 1, 2026, through August 31, 2027. The company will develop and validate a novel blood test diagnostic for detecting transthyretin amyloidosis, a progressive protein misfolding disorder affecting approximately 500,000 individuals in the United...
- Federal Grant Award Summary Primary Bioscience, Inc. received a $305,000 Small Business Technology Transfer (STTR) Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) effective July 15, 2025, with a completion date of June 30, 2026. The company is developing an ultra-sensitive biosensor capable of single-molecule protein analysis and sequencing. The technology integrates a nanopatterned chip with a proprietary amino acid and...
- The National Science Foundation (NSF) awarded a $305,000 Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant to Cicadea Biotech LLC, a women-owned small business, to develop a novel, non-invasive urine test for early detection of kidney cancer. The goal of this 17-month project is to demonstrate the specificity and accuracy of a biomarker to detect kidney tumors at an early stage, before symptoms appear, as well as its effectiveness in detecting residual disease in kidney cancer...
- Federal Cooperative Agreement Award Summary Adialante L.L.C. received a $1.19M Small Business Innovation Research (SBIR) Phase II award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) on June 15, 2025, with completion anticipated by November 30, 2026. The award supports the commercialization and development of an innovative head-only Magnetic Resonance Imaging (MRI) scanner platform designed to deliver clinical-quality brain imaging...
- Federal Grant Award Summary Folde Inc. received a $303,242 Phase I Small Business Innovation Research (SBIR) award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084), effective October 1, 2025, through September 30, 2026. The award funds development of a novel urinary catheter device designed to address difficult urethral catheterizations (DUCs), which occur approximately once per minute in U.S. medical settings and result in roughly 500,000...
- Federal Grant Award Summary Rumedical Nova LLC received a $305,000 Small Business Innovation Research (SBIR) Phase I project grant from the National Science Foundation (NSF) Directorate for Technology, Innovation, and Partnerships (CFDA 47.084) awarded July 15, 2026, with completion targeted for December 31, 2027. The awardee is developing a next-generation portable bio-chip platform designed to detect lung cancer biomarkers in body fluids such as blood serum with high sensitivity and rapid...
- Federal Grant Award Summary Ivsonance Biomedical Inc. received a $305,000 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) effective October 1, 2025, through September 30, 2026. The awardee, based in Ithaca, New York, is developing a semi-automated acoustic tweezer system that uses modulated sound waves to provide contactless micromanipulation of delicate biological materials...
- Federal Grant Award Summary Gelastomerics LLC received a $305,000 Phase I Small Business Innovation Research (SBIR) award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084), effective May 1, 2025 through April 30, 2028. The project focuses on research and development to establish the technical and commercial viability of a novel hydrogel elastomer technology designed to provide intrinsic lubricity for medical device applications. This...
- Federal Grant Award Summary Foli Bio Inc. received a $305,000 Phase I Small Business Innovation Research (SBIR) award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) to develop a high-throughput fecal exfoliome analyzing platform for clinical drug development. The award, initiated October 1, 2025, with completion targeted for September 30, 2026, funds the advancement of a stool-based diagnostic technology that captures and...
Federal Project Grant Award Summary Resolet Inc. received a $305,000 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation's Directorate for Technology, Innovation, and Partnerships (TIP) under CFDA 47.084, effective July 1, 2026, through June 30, 2027. The company is developing a compact, low-field magnetic resonance relaxometry sensor operating at 0.1 Tesla for measuring iohexol concentration in blood samples to assess kidney function. This benchtop diagnostic device aims to miniaturize core magnetic resonance imaging technology into a portable, radiation-free alternative to centralized laboratory-based methods, enabling point-of-care kidney function testing that addresses significant limitations in current endogenous biomarker estimates. The intended outcomes of this Phase I project include a rapid, accurate diagnostic tool for kidney disease assessment and early detection of kidney injury. By shifting testing from centralized laboratories to clinical bedside settings, the technology targets cost reduction and efficiency gains for hospitals and community clinics, particularly those lacking access to advanced diagnostics. The broader impact encompasses improved patient outcomes across transplant and primary care settings, with potential to benefit tens of millions of individuals living with kidney disease through faster and more reliable clinical decision-making for disease staging and patient management.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $305.0k | 6/17/26 |